spacer
home > ebr > summer 2018 > endonuclease compliance
PUBLICATIONS
European Biopharmaceutical Review

Endonuclease Compliance

A novel fermentative process, free of animal-based derivatives, uses endotoxin-free Bacillus amyloliquefaciens to economically produce the endonuclease from Serratia marcescens in high quantities. The new derivative is the first current Good Manufacturing Process (cGMP) product of its type, allowing its use in red biotechnology without regulatory restrictions.

Nucleases comprise a broad family of hydrolases that cleave nucleic acids. Several biotechnological applications have been reported, for example, in removing nucleic acids in biosynthetic processes to reduce viscosity associated to cell disruption or in the cost-effective elimination of nucleic acid impurities of a final (biosynthetic) product to comply with tight safety regulations. The production of the endonuclease from S marcescens has recently been successfully demonstrated in Bacillus subtilis − a gram-positive, endotoxin-free bacterium. Moreover, the fermentation is conducted in the absence of animal-based derivatives, thus, the novel derivative is an animal-free ingredient without the risk of bovine spongiform encephalopathy and transmissible spongiform encephalopathy (BSE/TSE). On that basis, the new endonuclease fulfils all cGMP requirements and may significantly broaden the applications of nucleases in biopharmaceuticals, promoting new markets and stimulating established ones.

Applying Nucleases

Nucleases are hydrolases that cleave the phosphodiester bonds between monomers of nucleic acids (DNA and RNA), digesting them into smaller oligonucleotides. In nature, they are responsible for the proper maintenance of nucleic acids in cells, keeping the genetic quality control and being actively involved in DNA replication and reparation. Some unspecific nucleases display the cleavage of all forms of nucleic acids, namely DNA and RNA, single- or double-stranded, linear or circular, and without any defined sequence-specificity. In the realm of red biotechnology and molecular biology sciences, such nucleases have become useful biocatalysts for a broad number of applications. A remarkable example is the purification of biopharmaceuticals – for instance, biosynthesised proteins, vaccines, etc – by removing the nucleic acid impurities generated along the bioprocess, thus saving costs associated to the downstream processing and purification units. Another useful application is the reduction of viscosity in biological samples caused by the presence of nucleic acids when cells are disrupted during the work-up steps.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Pablo Domínguez de María holds BScs in pharmacy and chemistry and a PhD in biocatalysis. He worked in the industry for 6.5 years at Evonik from and AkzoNobel BV, being involved in projects related to sustainable chemistry, organocatalysis, biorefineries, and biotech. In 2009, Pablo joined the RWTH Aachen University, Germany, as group leader, defending his habilitation in 2015. Since 2014, he is the CEO of Sustainable Momentum, a consultancy firm providing technical support in areas related to biorefineries, biotech, and sustainable chemistry. He has delivered several technical books, is co-inventor of some patents, and has published more than 100 scientific publications.

Dr Stefan Schoenert is Head of Strain and Process Development at c-LEcta. He was the developer of DENARASE nuclease and is responsible for development and improvement of biotech-relevant expression systems based on microorganisms including Bacillus sp, E coli, and Pichia pastoris and their use in production of enzymes and organic chemicals. Stefan has a PhD in biology from the University of Konstanz, Germany.
spacer
Dr Pablo Domínguez de María
spacer
spacer
spacer
Dr Stefan Schoenert
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

PDA Universe of Pre-Filled Syringes and Injection Devices

8 October - 9 November 2018, Loews Royal Pacific, Orlando, FL

At the 2018 PDA Universe of Pre-filled Syringes and Injection Devices,industry and regulatory experts will share experiences, new developments, regulatory considerations, challenges, and industry trends and best practices. This is a must-attend event for all industry professionals involved in the development, manufacturing, testing, or marketing of pre-filled syringes and injection devices.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement